Thrivent Financial For Lutherans boosted its stake in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 10.7% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 40,540 shares of the biotechnology company’s stock after purchasing an additional 3,920 shares during the period. Thrivent Financial For Lutherans owned 0.06% of Momenta Pharmaceuticals worth $685,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. PNC Financial Services Group Inc. boosted its position in Momenta Pharmaceuticals by 0.4% during the second quarter. PNC Financial Services Group Inc. now owns 76,863 shares of the biotechnology company’s stock valued at $1,299,000 after purchasing an additional 303 shares during the last quarter. Profund Advisors LLC raised its stake in Momenta Pharmaceuticals by 13.1% in the second quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock valued at $223,000 after buying an additional 1,530 shares during the period. Edmond DE Rothschild Holding S.A. raised its stake in Momenta Pharmaceuticals by 4.8% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 440,000 shares of the biotechnology company’s stock valued at $7,436,000 after buying an additional 20,000 shares during the period. BlackRock Inc. raised its stake in Momenta Pharmaceuticals by 7.1% in the second quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock valued at $158,868,000 after buying an additional 626,415 shares during the period. Finally, Nationwide Fund Advisors raised its stake in Momenta Pharmaceuticals by 11.9% in the second quarter. Nationwide Fund Advisors now owns 126,094 shares of the biotechnology company’s stock valued at $2,131,000 after buying an additional 13,382 shares during the period. 93.88% of the stock is owned by hedge funds and other institutional investors.

Several analysts have issued reports on the company. Zacks Investment Research lowered Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Barclays PLC restated an “equal weight” rating and issued a $16.00 price objective (down previously from $17.00) on shares of Momenta Pharmaceuticals in a research note on Wednesday, October 4th. Stifel Nicolaus restated a “buy” rating and issued a $26.00 price objective on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd. BidaskClub lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Finally, Goldman Sachs Group, Inc. (The) restated a “neutral” rating and issued a $14.00 price objective (down previously from $18.00) on shares of Momenta Pharmaceuticals in a research note on Thursday, October 5th. Three research analysts have rated the stock with a sell rating and nine have issued a hold rating to the stock. Momenta Pharmaceuticals has an average rating of “Hold” and a consensus target price of $15.00.

In related news, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total value of $678,743.01. Following the transaction, the president now owns 286,121 shares in the company, valued at $5,444,882.63. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $15.07, for a total value of $62,028.12. Following the completion of the transaction, the president now owns 269,231 shares in the company, valued at approximately $4,057,311.17. The disclosure for this sale can be found here. In the last quarter, insiders sold 79,663 shares of company stock worth $1,414,498. 4.40% of the stock is owned by company insiders.

Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) EPS for the quarter, meeting the consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The business had revenue of $23.57 million for the quarter, compared to the consensus estimate of $24.64 million. During the same quarter in the prior year, the business earned ($0.31) earnings per share. Momenta Pharmaceuticals’s revenue for the quarter was down 10.8% on a year-over-year basis.

COPYRIGHT VIOLATION NOTICE: “Thrivent Financial For Lutherans Buys 3,920 Shares of Momenta Pharmaceuticals, Inc. (MNTA)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/13/thrivent-financial-for-lutherans-buys-3920-shares-of-momenta-pharmaceuticals-inc-mnta.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Stock Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.